Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $14.37 in the prior trading day, Denali Therapeutics Inc (NASDAQ: DNLI) closed at $14.80, up 2.99%. In other words, the price has increased by $2.99 from its previous closing price. On the day, 1.51 million shares were traded.
Ratios:
Our goal is to gain a better understanding of DNLI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.56 and its Current Ratio is at 9.56. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 06 ’25 when Ho Carole sold 12,255 shares for $20.22 per share. The transaction valued at 247,796 led to the insider holds 178,580 shares of the business.
Ho Carole sold 2,907 shares of DNLI for $60,495 on Jan 07 ’25. The Chief Medical Officer now owns 175,673 shares after completing the transaction at $20.81 per share. On Jan 06 ’25, another insider, Schuth Alexander O., who serves as the COFO and Secretary of the company, sold 12,255 shares for $20.22 each. As a result, the insider received 247,796 and left with 247,215 shares of the company.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is 2.42%, while the 200-Day Moving Average is calculated to be -32.74%.
Shares Statistics:
A total of 145.25M shares are outstanding, with a floating share count of 125.76M. Insiders hold about 13.43% of the company’s shares, while institutions hold 87.93% stake in the company.
